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Phenylpropenes are produced by plants as part of their defense strategy against microorganisms 
and animals, and also as floral attractants of pollinators. Eugenol, the main component of 
clove’s essential oil, is an inexpensive and easily available phenylpropene that has been known 
by humankind since antiquity, and used as a medicinal agent, but also for food flavoring and 
preservation. The review includes the most relevant results obtained during the last 15 years with 
regard to the synthetic uses of eugenol. Discussed here are the multiple applications of eugenol in 
organic synthesis, including its use as starting material or building block for the total synthesis of 
natural products, their analogs and derivatives, as well as other structurally interesting or bioactive 
compounds. The preparation technologically relevant macrocycles and polymeric derivatives 
of eugenol, is included, and the impact of biotechnology on the use of eugenol as feedstock for 
biotransformations, leading to other valuable small molecules is also addressed.
Keywords: eugenol, natural products synthesis, polymer science, macrocycles, bioactive 
compounds
1. Introduction
All the major groups of angiosperms biosynthesize 
phenylpropenes. These are stored in their vegetative parts, 
as a defense against herbivores, parasitic bacteria and fungi, 
or are easily volatilized, being toxic to insects and microbes. 
In addition, sometimes they are emitted from flowers to 
attract insect pollinators. 
Eugenol (1 ,  Figure 1)1 is  one of these key 
phenylpropenes. The natural product is a major aromatic 
constituent (up to approximately 80% by weight) of 
the essential oil of clove [Eugenia caryophyllata L. 
Merr. & Perry (Myrtaceae) = Syzygium aromaticum], 
which is commonly obtained by hydrodistillation, steam 
distillation, or Soxhlet (ethanol) extraction from leaves, 
buds, and stems of clove trees (Myrtaceae).2 Eugenol 
is also found in Myristica fragrans Houtt. (nutmeg), 
Cinnamomum verum J. Presl (true cinnamon), C. loureirii 
Nees. (Saigon cinnamon), Ocimum gratissimum Forssk. 
(basil), Ocimum basilicum L. (sweet basil), pimento berry 
and bay oil, among others. 
Since the remote antiquity, medicinal plants have been 
the mainstay of traditional herbal medicine amongst rural 
dwellers worldwide. Natural products have been an integral 
part of the ancient traditional medicine systems including 
Ayurveda, Chinese and Egyptian. Currently, around 40% 
of the world population depends directly on plant based 
medicine for their health care. Hence, the traditional use of 
plants or parts of plants containing eugenol for medicinal 
purposes is not an exception.
Eugenol is a natural and generally acting antimicrobial 
and antianimal toxin, with mild analgesic properties. It 
is commonly used as a fragrance and flavoring agent in 
a variety of cosmetics, and food products. In addition, 
the natural product has shown a number of other 
interesting biological activities, including antioxidant, 
anti-inflammatory, antispasmodic, antidepressant, 
antigenotoxic, and anticarcinogenic. Proof of the interest 
in this subject is the surprisingly high number of articles 
reviewing these properties, which have been published in 
recent times.3 
On the other hand, methyl eugenol (4-allyl-1,2-
dimethoxybenzene, 2) is the methyl ether derivative of 
eugenol. This is also a natural product,4 which has a relevant 
role in nature, especially in relation to insect behavior 
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and pollination.5 This chemical is easily available and has 
attracted some attention to the point that a green chemistry 
condition for its access (by alkylation of eugenol with 
dimethyl carbonate),6 has been published. Compound 2 has 
been widely used as a test molecule for the development 
of organic synthetic methodologies,7 it enjoys widespread 
use in carbohydrate chemistry, as a reagent to scavenge the 
PhSOTf formed during sulfoxide glycosylations,8 and has 
found some applications as starting material or building 
block in organic synthesis.
Eugenol is commercially available in large quantities 
with a market price around US$ 5 per kg; however, despite 
its easy access, it has been recently used as target for 
synthesis by a metal-free photoallylation of aryl halides 
with allyl-tetramethylsilane (TMS) in a MeCN-H2O 
medium.9 The particular structure and ready availability of 
eugenol has turned the natural product into an interesting 
starting material and a useful building block for complex 
synthesis, as well as into a valuable substrate for various 
biotransformations.
In 2000, Costa et al.10 reviewed the chemical reactivity 
of eugenol and safrol, and their use in the synthesis of 
biologically active natural products and their derivatives. 
Therefore, in an attempt to complement and extend that 
work, this review will focus mainly on the advances which 
took place during the last 15 years, in the use of eugenol 
for different synthetic purposes. 
Topics covered range from eugenol being a feedstock 
for biotransformations to the applications of the natural 
product as suitable starting material or key building block 
toward the synthesis of other natural products and their 
analogs, bioactive compounds, heterocycles, macrocycles 
and polymers.11 However, the numerous applications of the 
related isoeugenol (3), a β-methylstyrene natural product, 
also available from eugenol, will not be covered.
2. Total Synthesis of Natural Products
Eugenol was found to be one of the most suitable 
starting materials for the total synthesis of structurally 
different natural products. Since various targets have 
been reached, the syntheses were grouped and arranged 
according to the type of objective, and a subjectively 
determined increasing degree of complexity.
2.1. Hydroxytyrosol and (E)-4-(4-hydroxy-3-methoxyphenyl)
but-2-enol
Among the wide variety of bioactive components 
found in olive oil, several phenolic compounds have been 
reported to express beneficial effects on human health.12 
The average concentration of phenolics can rise up to 
1 g kg−1 in the first-pressed ‘extra virgin’ type olive oil. 
Hydroxytyrosol (4) is a simple catecholic compound and 
one of the major phenolic compounds present in the olive 
fruit and olive oil, together with oleuropein (5), from which 
it can be generated by hydrolysis.13 
Due to its remarkable antioxidation activity,14 
hydroxytyrosol is suitable as a natural and non-toxic food 
preservative and a highly promising alternative to synthetic 
antioxidants. The natural product also contributes to the 
stability of virgin oil against rancidity caused by oxidation.15 
A two-pot four-step synthesis of 4 from eugenol 
(Scheme 1) was reported by Deffieux et al.16 The process 
was initiated by ozonolysis of the double bond of 1, 
followed by an in situ hydride reduction of the ozonide 
to afford alcohol 6 in 98% yield. However, subsequent 
cleavage of the methyl aryl ether bond with aluminum 
iodide17 and a catalytic amount of tetra-n-butylammonium 
iodide (TBAI) in MeCN,18 afforded only 54% of the 
expected product. Therefore, a better alternative toward 
4 was devised, through the dealkylative oxidation of 
the monomethyl catechol moiety of 6 with NaIO4 to the 
unisolated quinone 6a, followed by a reductive work-up with 
sodium thiosulfate, which furnished hydroxytyrosol (4) in 
an improved 78% yield.
On the other hand, (E)-4-(4-hydroxy-3-methoxyphenyl)
but-2-enol (7) was originally isolated from the roots of 
Zingiber cassumunar, a medicinal plant from Southeast 
Asia possessing antioxidant and antiinflammatory 
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Figure 1. Chemical structures of eugenol (1), methyleugenol (2) and 
isoeugenol (3).
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Scheme 1. Reagents and conditions: (a) 1. O3, EtOH; 2. NaBH4, 
EtOH (98%); (b) AlI3, TBAI, MeCN, reflux (54%); (c) NaIO4, EtOAc; 
(d) Na2S2O4 (work-up, 78% overall); (e) Grubbs II in paraffin, cis-2-
butene-1,4-diol, petroleum ether, room temperature (RT), 12 h (98%).
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properties.19 Taber et al.20 performed a single-step synthesis 
of 7 from eugenol, by cross-metathesis with cis-2-butene-
1,4-diol, and employing Grubbs II catalyst embedded in 
paraffin wax. Similarly, direct self-metathesis, and cross-
metathesis of eugenol with symmetrical internal olefins 
and other alkenes,21 and the use of ruthenium-catalyzed 
olefin cross-metathesis of eugenol with electron deficient 
olefins for the synthesis of polyfunctional alkenes have 
been reported.22 
2.2. 6-Gingerol
6-Gingerol (8) is the key phenolic compound isolated 
from the rhizomes of ginger (Zingiber officinale Roscoe), 
a food spice and an important ingredient in Ayurvedic, 
Tibb-Unani and Chinese herbal medicines, for the treatment 
of various ailments like catarrh, rheumatism, gingivitis, 
toothache, asthma, stroke, constipation, and diabetes.23 
6-Gingerol is responsible for the flavor and pungency of 
the spice, as well as for its bioactivity as antioxidant,24 
anti-inflammatory,25 anti-tumor-promoting,26 anti-platelet 
aggregation,27 and antibacterial agent.28 
Isolation of this natural product is complicated by its 
low abundance and the presence of homologs and other 
structurally similar compounds. Therefore, Bettadaiah 
and co-workers29 performed a total synthesis of 6-gingerol 
from eugenol (Scheme 2). To that end, these authors first 
protected its phenolic group as benzyl ether (9) and then 
converted the double bond into the primary iodide 10 in 
75% yield, by hydroboration followed by iodination.30 
Further transformation of the iodide 10 into the 
corresponding nitro derivative was best achieved with silver 
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Scheme 2. Reagents and conditions: (a) BnBr, K2CO3, MeCN, RT, 4 h 
(98%); (b) 1. NaBH4, I2, THF, 0 °C, 2.5 h; 2. 9, RT, 3 h; 3. NaOMe, I2, 
0 °C, 3 h (75%); (c) AgNO3, NaNO2, H2O, RT, 10 h (75%); (d) Ac2O, 
4-dimethylaminopyridine (DMAP), CH2Cl2, RT, 5-6 h (85%); (e) Ra-Ni, 
H2 (30 psi), EtOH, 6 h; (f) Pd/C, H2, EtOH, 3 h (60%, overall). 
nitrate and sodium nitrite, which afforded 11 in 75% yield. 
In turn, this was subjected to a [3+2] cycloaddition reaction 
with 1-heptene in the presence of Et3N and Ac2O, to provide 
40% of the intermediate isoxazoline 12.31
The thus prepared heterocycle 12 was hydrogenolyzed 
in the presence of Raney nickel in moist ethanol to afford 
β-hydroxy carbonyl intermediate 13, which was further 
debenzylated to furnish 8, by catalytic hydrogenolysis 
with Pd/C, furnishing 60% of 8. Interestingly, a chiral 
difluorinated analog of 6-gingerol (8a) was previously 
synthesized from eugenol, employing a different 
approach.32
2.3. Cimiracemate B
The cimiracemates are phenylpropanoic acid esters 
isolated from the rhizomes of Cimifuga racemosa.33 
The plant containing these natural products is used in 
traditional medicine to treat menopausal symptoms34 and 
inflammation.35 In addition, it has been shown recently 
that cimiracemates could have additional health benefits, 
as scavengers of reactive oxygen species.36 
However, the natural products are produced in extremely 
low amounts, as the abundance of cimiracemate B (14) is 
only 6 parts per million of the dry weight of the methanolic 
extract of the rhizome. Therefore, Piva and co-workers37 
reported a concise and convergent total synthesis of 
cimiracemate B (Scheme 3) starting from eugenol (1). 
Related compounds were also synthesized employing the 
same strategy.
The synthesis entailed the coupling of building blocks 
derived from eugenol (17) and cinnamic acid (20). For 
the synthesis of the former, eugenol (1) was protected as 
the tert-butyldimethylsilyl (TBS) ether 15 in 90% yield, 
which was converted into bromohydrin 16 under mild 
conditions with N-bromosuccinimide (NBS) in aqueous 
dimethyl sulfoxide (DMSO), thus avoiding the cleavage of 
the protecting group.38 This was followed by a Dess-Martin 
oxidation39 toward ketone 17, which was accessed in 78% 
yield. 
On the other hand, the synthesis of the cinnamic 
acid component 20 was performed in 81% overall 
yield by exhaustive silylation of 18 to the bis-silyl 
derivative 19, followed by mild and selective hydrolysis 
of the silyl ester moiety (20).40 The coupling between 
the acid and the α-bromoketone was achieved under 
phase transfer catalysis, resulting in 57% of the bis-
silylated cimiracemate B derivative 21, which was finally 
deprotected to furnish 14, with aqueous HF in acetonitrile 
in rather low yield,41 due to the lability of the ester 
bond.
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2.4. Imperanene
Imperanene (22), a phenolic compound which displays 
the rare C6-C4-C6 pattern, was isolated from the rhizomes 
of Imperata cylindrica.42 In traditional Chinese medicine, 
this plant is used as an anti-inflammatory and diuretic agent. 
However, in rabbits, the compound completely inhibits 
thrombin-induced platelet aggregation at concentrations 
as low as 6-10−4 mol L−1. Other members of this rare class 
of natural products have also shown biological activity, as 
antiplatelet aggregation agents.43 
The search for new platelet aggregation inhibitors 
to treat conditions such as heart attack, and the need to 
elucidate the absolute configuration of the natural product, 
prompted Shattuck and co-workers44 to devise a total 
synthesis of both enantiomers of 22, which was carried out 
in eight steps and 82-90% ee from eugenol (1).
The total synthesis of 22 (Scheme 4) was initiated 
with the protection of eugenol as the silyl ether 15, in 
78% yield. This was followed by the hydroboration of 
the double bond with disiamyl borane, and furthered 
by oxidation of the organoborane intermediate to the 
aldehyde 23 with pyridinium chlorochromate (PCC), in 
75% yield. 
Access to the aldehyde 23 set the stage for the 
diastereoselective introduction of the hydroxymethyl side 
chain (25), which was performed in approximately 80% 
yield via the asymmetric alkylation of the corresponding 
Enders’ hydrazone (24) and its enantiomer, with BOMCl.45 
The hydrazones 24 were prepared in high yield by reaction 
of 23 with (S)-1-amino-2-methoxymethylpyrrolidine 
(SAMP) and the (R)-enantiomer (RAMP), as chiral 
auxiliaries.46 Only the route employing SAMP is shown.
The chiral auxiliary was removed ozonolytically to form 
the aldehyde 26, and chiral acetal 27 was prepared with 
the aid of (R,R)-diol derivative 28, in order to determine 
its enantiomeric excess by nuclear magnetic resonance 
(NMR) spectroscopy, employing Eu(fod)3 as chiral shift 
reagent.47 On the other hand, the aldehyde 26 was coupled 
under optimized conditions with the Wittig reagent 29, 
furnishing alkene 30 in a ca. 5:1 E/Z ratio. 
Transprotection of the benzyl group into a TMS 
ether (31) in 65% yield, followed by fluordesilylation with 
TBAF, enabled the smooth removal of both silicon-based 
protecting groups and afforded 22 in 82% yield. This 
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Scheme 3. Reagents and conditions: (a) tert-Butyldimethylsilyl chloride 
(TBDMSCl), imidazole, 4-dimethylaminopyridine (DMAP), CH2Cl2 
(90%); (b) NBS, H2O-DMSO (5:95), 0 °C, (78%); (c) Dess-Martin, 
CH2Cl2 (78%); (d) TBDMSCl, imidazole, DMAP, CH2Cl2 (90%); 
(e) K2CO3, tetrahydrofuran (THF), MeOH, 30 min, RT (90%); (f) NaOH 
(aq.), nBu4NBr, toluene, RT, 12-14 h (57%); (g) 1. HF (aq.), MeCN, RT, 
30 min; 2. 8% NaOH (10%).
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Scheme 4. Reagents and conditions: (a) TBSCl, imidazole, 
dimethylformamide (DMF), RT, 19 h (78%); (b) 1. disiamylborane, 0 °C, 
3 h; 2. PCC, CH2Cl2, reflux, 2 h (75%); (c) SAMP, 0 °C → RT, 20 h (84%); 
(d) 1. lithium di-isopropyl amide (LDA), 0 °C, 5.5 h; 2. benzyloxymethyl 
chloride (BOMCl), −120 °C, 20 min, then RT, 20 h (77%); (e) nBuLi (2 
equiv.), 29 (2 equiv.), THF, 0 °C, 30 min → RT, 19 h (30, 72%); (f) PhSSiMe3 
(10 equiv.), nBu4NI (1.5 equiv.), ZnI2 (5 equiv.), 1,2-dichloroethane (DCE), 
RT (31, 65%); (g) tetra-n-butylammonium fluoride (TBAF) (3.3 equiv.), 
THF, RT, 30 min (22, 82%); (h) O3, CH2Cl2, −78 °C, 30 min (79%); 
(i) TMSOTf (cat.), CH2Cl2, −78 °C, 3 h, then 0 °C, 1 h (76%).
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(b) MeI, K2CO3, DMF, 2 h, RT (90%); (c) 4-HO–C6H4CH2CH=CH2, 
Cs2CO3, CuI, N,N-dimethylglycine hydrochloride, dioxane, 90 °C, 48 h 
(75%); (d) BBr3, CH2Cl2, 30 min, −78 °C, RT, 2 h (75%). 
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DMAP, pyridine, CH2Cl2 (83%); 2. CH2=CHCH2SiMe2Cl, Et3N, CH2Cl2 
(86%); (e) Grubbs II, CH2Cl2, ∆ (75%); (f) BF3·OEt2, CH2Cl2; (g) 1. OsO4, 
KIO4, THF-H2O (95% from 45; 91% from 46); 2. LiAlH4, THF, –60 °C 
(37, 84%; 38, 90%). 
strategy avoided product instability associated with the 
hydrogenolytic debenzylation.
2.5. Obovatol
Obovatol (32) was isolated from a Magnolia species, 
which bark has traditionally been used in East Asia as a 
folk remedy for gastrointestinal disorders, cough, anxiety 
and allergic diseases.48 The natural product was found to 
inhibit nitric oxide production, and the enzymes chitin 
synthase 2 and acyl-CoA:cholesterol acyltransferase.49 
Recently, it was also reported that obovatol has antitumor 
and anti-inflammatory activity through inhibition of 
NF-κB, a transcriptional factor significant to control cancer 
cell growth activity, and that this diaryl ether compound 
could be effective against photo-damaged skin.50 
Jung and co-workers51 recently reported a concise, 
four-steps total synthesis of the natural product (Scheme 5) 
from eugenol (1), which proceeds in 40% overall yield and 
relies on a chemoselective ortho-bromination of a phenol 
in the presence of a double bond. 
Therefore, treatment of eugenol with i-PrMgCl as a base 
and 1,3-dibromo-5,5-dimethylhydantoin as an electrophile 
afforded 78% of bromoarene 33.52 Methylation of 33 
furnished 90% of 34, the required precursor for the diaryl ether 
coupling with p-allylphenol (35). This reaction was better 
performed under the conditions of Ma, affording 75% of the 
Ullmann product 36, uncontaminated with β-methylstyrene 
derivatives resulting from double bond conjugative 
migration.53 Final demethylation of the coupling product 
36 with BBr3 afforded 75% of the synthetic obovatol (32). 
2.6. Dihydrodehydroconiferyl alcohols
Neolignans are widely distributed natural products, 
which act as plant defense substances.54 They also exhibit 
important biological activities as antitumor agents, 
bactericides, enzymatic inhibitors, antioxidants, etc. 
Several neolignans have been totally synthesized from 
eugenol, employing different approaches. 
Cis- and trans-dihydrodehydro diconiferyl alcohols (37) 
are neolignans that were isolated from the twigs of 
Taxus mairei.55 Rodríguez-García and co-workers56 devised 
a six-step synthesis of neolignan 37 and its O-methyl analog 
38 carrying a dihydrobenzo[b]furan skeleton (Scheme 6), 
based on a ring-closing metathesis reaction to produce 
a benzo[f][1,2]oxasilepine (43) intermediate, which was 
condensed with aromatic aldehydes 44, in a modified 
Sakurai-Hosomi reaction.57 
To that end, eugenol (1) was submitted to a hydroboration-
oxidation reaction, which gave 84% of a mixture containing 
mainly the primary alcohol 39. Subsequent allylation of 
the free phenol afforded 83% of the allyl ether 40, which 
was subjected to sequential Claisen rearrangement and 
double bond isomerization with NatBuO, furnishing 41 
quantitatively. 
Selective protection of the alcohol as pivalate 
(83% yield) and silylation of the phenolic OH with 
allylchlorodimethylsilane, provided the intermediate 
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allylsiloxane 42 (86% yield) and set the stage for a ring-
closing metathesis with Grubbs II catalyst, which gave the 
key benzo[f][1,2]oxasilepine 43 in 75% yield. 
The modified Sakurai-Hosomi reaction of 43 with 
aldehydes 44a,b under promotion by BF3·OEt2 took place 
without diastereoselectivity,58 affording 1:1 mixtures of 
the cis- and trans- dihydrobenzofurans 45 and 46 (70-78% 
yield), the relative stereochemistry of which was assigned 
after NMR analysis. Finally, oxidative fission of the 
double bond with OsO4/KIO4 afforded the corresponding 
aldehydes, whereas subsequent treatment with LiAlH4 
effected the simultaneous reduction of the aldehyde and 
deprotection of the pivalate ester, furnishing the target 
neolignans 37 and 38 in 84% and 90% yield, respectively. 
2.7. Carinatol
Carinatol (47) is a neolignan isolated from the 
bark of Virola carinata, a tropical evergreen tree in the 
Myristicaceae family that is indigenous to Colombia, 
Venezuela and Brazil.59 For the total synthesis of this 
natural product (Scheme 7), phosphamidate 50 was 
prepared in three steps and 94% yield from eugenol, 
by means of protection of the free phenol of 1 as the 
phosphamidate 48, followed by heteroatom-directed ortho 
metalation-alkylation to 49 and final lateral metalation-
methylation. 
The ethylarene derivative 50 was submitted to an 
additional lateral metalation, at the benzylic methylene 
group ortho to the phosphamidoyl group, and reacted 
with 3,4-dimethoxy benzaldehyde (51), furnishing a 77:23 
(anti:syn) mixture of carbinols 52 in 71% yield. Then, the 
phosphamidoyl protecting group was reductively removed 
in 53% yield toward phenol 53, which was subsequently 
cyclized in 41% yield under acidic conditions, to afford 
carinatol (47).60 
2.8. XH-14 
The neolignan XH-14 (54) was isolated from the plant 
Salvia miltiorrhiza and found to be a potent antagonist of 
the A1 adenosine receptor.61 Scammells and co-workers62 
reported a short total synthesis of the natural product from 
eugenol (Scheme 8).
The synthesis was initiated with the hydroboration-
oxidation of the double bond of 1, with BH3.SMe2, 
followed by selective protection of the resulting primary 
alcohol 39 (obtained in 84% yield) with Ac2O and 
BF3.Et2O,63 which afforded 77% of a 92:8 mixture of 
mono- and di-acetylated compounds 55 and 55a. Taking 
advantage of the activating and directing potential of the 
free phenol, 55 was selectively ortho-brominated with NBS 
in the presence of diisopropylamine, affording 39% of 56.64 
In turn, the bromide 56 was coupled with cuprous 
(4-benzyloxy-3-methoxy)phenyl acetylide (57) to afford 
65% yield of 58, which was subjected to catalytic 
debenzylation toward 58, furnishing 92% of the product. 
Final formylation of 59 using a Gatterman-Adams reaction 
resulted in 59% yield of XH-14 (54).
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2.9. Eupomatenoids 17 and 18
The eupomatenoids are a class of neolignans, which 
exhibit insecticidal, antimicrobial, antioxidant, and 
antitumor activity.65 Eupomatenoid 17 (60) was isolated from 
Eupomatia bennetti F. Muell,66 whereas eupomatenoid 18 
(61) was obtained from Virola pavonis, Eupomatia bennetti 
F. Muell, and the bark of Virola carinata (Myristicaceae).67 
Dong and co-workers68 devised short syntheses 
of eupomatenoids 17 and 18, which employ a fully 
functionalized vinylphenol derived from eugenol and 
a hydroacylation and cyclocondensation/dehydration 
reaction to forge the benzofuran core (Scheme 9). 
The synthesis of the eugenol derived component 63 was 
performed in two steps, by Duff formylation of 1, which 
proceeded in 30% yield, followed by Wittig olefination 
of the resulting aldehyde 62 (82% yield). The vinyl 
phenol 63 was then coupled with benzaldehydes 64 and 
51 under rhodium catalysis, furnishing the corresponding 
hydroacylation products, the ketones 66 and 67, through 
the intermediacy of 65. In turn, the phenolic ketones were 
cyclodehydrated with TFA, affording 78% and 82% of the 
targets 60 and 61, respectively.
2.10. Santalin B
Red sandalwood, a rare hardwood, obtained from the 
tree Pterocarpus santalinus and related species, is one 
R
MeO
CHO
R
MeO
Me
HO
OMe
O
HO
OMe
63
OMe
O
Me
MeO
R
60 61R = H; R = OMe
c
d
HO
OMe
HO
OMe
a
1 62
OHC
b
Rh
O
O
MeO
R
H
P
P
65
MeO
Allyl
64 51R = H; R = OMe
66 67R = H; R = OMe
Scheme 9. Reagents and conditions: (a) Hexamine, AcOH, 125 °C 
(30%); (b) PPh3MeBr, nBuLi, THF, 0 °C → RT (81%); (c) Rh(COD)
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dioxane, 70 °C, 24 h; (d) trifluoroacetic acid (TFA), CH2Cl2 (1:20), 40 °C, 
3 h (60, 78%; 61, 82%, overall).
of the colored materials found in nature that has been 
valued for millennia. In China, it was once reserved 
for the furniture of the imperial household, whereas in 
Ayurvedic medicine it is used for treating digestive tract 
problems and coughs. 
Despite chemical investigations of its colored 
constituents date back to the famous Pelletier,69 the 
chemical structures of the santalins A and B (68, 69) and 
the santarubins A and B (70, 71), were unequivocally 
demonstrated in 1975.70 These heterocycles, which 
share a common 9 h-benzo[a]xanthen-9-one core, were 
synthesized in 2013 by Strych and Trauner (Scheme 10),71 
employing pyrilium salt 72 as a common precursor, and 
a biomimetic strategy based on a previous speculation.72 
Their work demonstrated that complex molecular scaffolds 
can be assembled along biosynthetic lines, without the need 
of enzymatic catalysis. 
The synthesis of santalin B (69) was performed by 
reaction of the building blocks 81 and benzylstyrene 82. 
For the preparation of 82, aldehyde 84,73 easily available in 
three steps from resorcinol (83), was subjected to a Wittig 
olefination to afford 63% of the β-methylstyrene 85, as a 
2.1:1 mixture of diastereomers. In turn, the mixture was 
submitted to a Grubbs II catalyst mediated olefin cross-
metathesis reaction74 with eugenol (1) to yield 41% of the 
expected benzylstyrene 82 after desilylation. 
On the other hand, the synthesis of 81 commenced 
with esculetin (73), easily available in 52% yield from the 
H2SO4-mediated condensation of 1,3,4-trisacetoxybenzene 
83(a) with malic acid, at 120 °C for 2.5 h.75 Esculetin was 
protected in 96% yield as the bis(silyl ether) 74 before it was 
subjected to a palladium-catalyzed cross-coupling76 with 
bromoarene 76 via the di-organozinc intermediate 75, to 
afford 84% of the isoflavonoid derivative 79. Compound 76 
was accessed in 95% overall yield from phenol 77 through 
the intermediacy of aryl bromide 78.77
Compound 79 was then selectively reduced with 
DIBAL-H in 85% to the lactol 80, which upon treatment 
with HClO4 in AcOH, underwent protonation and 
subsequent dehydration with concomitant desilylation to 
furnish 76% of the isoflavylium perchlorate 72. 
Attempts to effect the biomimetic cascade reaction 
between isoflavylium perchlorate 72 and 82 in the presence 
of different bases met with limited success. However, 
santalin B (69) could be accessed in 62% yield when the 
isoflavylium salt was deprotonated in 89% yield to the 
anhydrobase 81 with 2,6-bis-tert-butylpyridine and then 
reacted with 82 under aerobic conditions. The mildness 
of the conditions of this final reaction raised the question 
whether the cycloaddition/oxidation cascade could take 
place spontaneously in nature.
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2.11. (−)-Plicatic acid
Plicatic acid (83) was isolated from western red cedar 
(Thuja plicata) and its structure was spectroscopically 
elucidated.78 This lignan has an unusual skeleton, that 
is densely functionalized and bears a motif of three 
contiguous (quaternary-quaternary-tertiary) stereocenters. 
Plicatic acid has been shown to cause inflammatory 
and allergic reactions, which are characterized by 
increased concentrations of immunoglobulins, histamine, 
leukotrienes, eosinophils, and T-cell levels in the blood.79 
Furthermore, the natural product has been identified as the 
causative agent of occupational asthma.80
With the aim of gaining access to analogues that could 
be valuable for biomedical studies aimed to elucidate the 
molecular mechanism underlying the biological activities 
of plicatic acid, Deng and co-workers81 performed the 
first asymmetric total synthesis of the natural product 83 
(Scheme 11), employing eugenol (1) as starting material.
Thus, benzylation of eugenol to yield 9, followed 
by oxidative cleavage of the olefin moiety afforded 
quantitative yield of the known aldehyde 84, which was 
efficiently converted (92%) into β-ketoester 85.82 In turn, 
the Knoevenagel condensation of 85 and 87 gave a 5:3 E/Z 
separable mixture of olefins 86. Since Z-86 was readily 
isomerized to E-86 with pyridine in refluxing benzene, it 
could be easily recycled, raising the overall yield of E-86 
to 80% in one cycle of the Knoevenagel condensation-
isomerization process. 
A modification of Seebach’s asymmetric epoxidation 
with (S,S)-TADOOH as terminal oxidant83 furnished 83% 
of epoxide 88 in 98% ee, whereas the regioselective Friedel-
Crafts reaction leading to 89 (as a 4:1 diastereomeric 
mixture with 89a, in favor of the desired diastereomer) 
was optimally performed in 70% yield, in the presence of 
trifluoromethanesulfonic acid (TfOH). Only the R-hydroxy 
ketone was isolated. Interestingly, broad and split peaks 
were observed in the 1H and 13C NMR spectra of this and 
more advanced intermediates, including the final product, 
resulting from the atropisomerism arising from the hindered 
rotation along the C1−C7’ bond. 
The easy enolizability of the ketone forced to implement 
the stereoselective addition of the hydroxymethyl group 
to the carbonyl, as an intramolecular stereospecific 
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Scheme 10. Reagents and conditions: (a) 1. TBSCl, imidazole, DMF, RT, 4 h (45%); 2. MgCl2, (CH2O)n, Et3N, THF, 70 °C, 2.5 h (87%); 3. MeI, Ag2O, 
Et2O, RT, 10 h (81%); (b) PPh3EtBr, BuLi, THF, RT, 2 h (63%); (c) 1. Grubbs II (0.1 equiv.), CH2Cl2, 50 °C, 8 h (85%); 2. TBAF, THF, RT, 30 min (48%); 
(d) TBSCl, imidazole, DMAP (cat.), DMF, RT, 3 h (96%); (e) 1. (TMP)2Zn.MgCl2.2LiCl, THF, RT, 1 h; (f) 76, Pd(OAc)2 (5 mol%), SPhos (10 mol%), 
PhMe, 65 °C, 2 h (84% overall); (g) DIBAL-H, CH2Cl2 (85%); (h) HClO4 (8 equiv.), AcOH, RT, 9 h (76%); (i) 2,6-di-tert-butyl pyridine, MeCN, 0 °C, 
10 min (89%); (j) 82 (2.5 equiv.), MeCN/ MeOH (5:1), 80 °C (62%); (k) Br2, CCl4, −10 °C, 5 min (98%); (l) TBSCl, imidazole, DMAP (cat.), DMF, RT, 
45 min (96%). 
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ee = 98%); (f) TfOH (4 mol%), CH2Cl2, −10 °C → RT, 15 min (89, 70%; 89a, 17%); (g) ClSi(Me)2CH2Br, imidazole, DMF, RT, 1 h (75%; 94% brsm); 
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addition of a masked hydroxymethyl group to the ketone, 
performing the critical C−C bond formation under nearly 
neutral conditions. Therefore, 89 was first silylated with 
ClSi(Me)2CH2Br to yield 75% of 90, which underwent a 
SmI2-mediated, intramolecular Barbier reaction84 in the 
presence of NiI285 to afford 59% of silanol 91. 
The Fleming-Tamao-Kumada86 oxidation of 91 
furnished triol-ester 92 in 50% yield, the treatment of which 
with sodium propanethiolate afforded 97% of the sodium 
carboxylate 93.87 Exhaustive catalytic debenzylation of 
93, followed by treatment with a cationic exchange resin 
furnished 72% of synthetic (−)-plicatic acid (83).
2.12. Schefferine
Schefferine (tetrahydropalmatrubine, 94) was isolated 
from the bark of Schefferomitra subaequalis Diels 
(Anonaceae), a New Guinea liana found as a climber 
on rain forest trees.88 Schefferine was postulated as key 
intermediate in the biosynthesis of sinactine from reticuline 
and as a precursor of tetrahydropalmatine.89
Ponzo and Kaufman90 reported a convenient entry into 
3-substituted tetrahydro-isoquinolines like schefferine 
(Scheme 12), featuring the reaction of silicon-based 
nucleophiles with tosyliminium ions, generated upon 
addition of Lewis acids to tosylamidals and employed 
this strategy for the synthesis of a natural product.91 By 
capturing the resulting tosyliminium ions with electron 
rich aromatics, such as phenols and their ethers, Bianchi 
and Kaufman92 extended the scope of this transformation to 
the elaboration of 3-aryl tetrahydroisoquinolines and also 
performed a total synthesis of schefferine.93 
Thus, the known amidal 95 was reacted with 
methyleugenol (2) under BF3·Et2O promotion, to afford 
88% of the 3-aryl tetrahydroisoquinoline derivative 96. 
Next, a two-step dihydroxylation of 96 with OsO4-NMO 
followed by a further treatment of the resulting diols 97 
with NaIO4 gave 89% of aldehyde 98 avoiding its over-
oxidation. The latter was reduced with NaBH4 to furnish 
92% of alcohol 99. 
The reaction of 99 with sodium in liquid ammonia94 
was found to cleanly effect the simultaneous cleavage of 
both, the benzyl and tosyl protective groups,95 providing 
amino alcohol 100 in 83% yield. Finally, the intramolecular 
Mitsunobu amination of 100 with the DEAD-PPh3 couple 
in THF containing 1 equivalent of HBF4 afforded 82% 
of schefferine (94). The addition of HBF4 provoked 
protonation of the DEAD-derived hydrazide anion 
intermediate, avoiding its involvement as a competing 
nucleophile in the amination process.96 
2.13. Ningalin C
Ningalin C (110) is a novel pyrrole-type aromatic 
alkaloid, isolated in 1997 together with other three 
congeners, from an unidentified ascidian of the genus 
Didemnum collected in ascidia-rich habitats near the 
Ningaloo Reef region, at the northwest cape of Western 
Australia.97 Biogenetically, the ningalins appear to be derived 
from the condensation of 3,4-dihydroxyphenylalanine 
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(DOPA).98 Compound 110 exhibits anti-cancer activity, 
because of its ability to reverse multi drug resistance.99
The Namsa-aid-Ruchirawat synthesis of ningalin C 
(Scheme 13)100 commenced with the Heck-type 
palladium-catalyzed coupling reaction101 between methyl 
2-bromoveratrate (102) and methyleugenol (2); this 
afforded 65% of ester 103, which was further cyclized102 
with LDA to naphthol 104 (76%).103 Next, oxidation of 
naphthol 104 with acidic H2O2 containing a trace of iodine, 
afforded 62% of the expected naphthoquinone 105, which 
was converted into the key aminoquinone intermediate 107 
by nucleophilic addition of homoveratrylamine (106).104 
Treatment of the aminonaphthoquinone 107 with 
the carbanion of methyl homoveratrate (108) effected 
the selective addition of the anionic species to the right 
ketone group of 107, in a process that was completed 
with the cyclization and subsequent dehydration towards 
the lactam, generating the pyrrolinone system of the 
ningalin C skeleton 109 in 69% yield, accompanied by 
9% of the hydrated product 110. The latter could be 
quantitatively dehydrated toward 109 by acid treatment. 
Finally, permethyl ningalin C (109) was demethylated105 
with BBr3 to give 72% of ningalin C (101).
2.14. (−)-Platensimycin
(−)-Platensimycin (111) was isolated from Streptomyces 
platensis MA7327, which originated from South Africa,106 
after a massive screen of 250000 extracts. Compound 111 is 
a potent inhibitor of fatty acid synthase that holds promise 
of being useful for the treatment of metabolic disorders, 
such as diabetes and “fatty liver”, and pathogenic infections 
caused by drug-resistant bacteria. Eey and Lear107 reported 
an original approach towards a key intermediate for the 
natural product starting from eugenol (1), which was later 
used for its total synthesis (Scheme 14).108 
The first intermediate 117 was prepared in 75% overall 
chemical yield and 91% ee, in 7 steps from eugenol (1). 
The sequence entailed the O-benzylation of the free phenol 
of eugenol to give 9, followed by a two-stage oxidative 
fission of the alkene toward 84, through the intermediacy 
of the diol 112. Next, olefination of the aldehyde 84 
with phosphorane 113 followed by LiAlH4-mediated 
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reduction of the resulting ester furnished 88% of 114, 
which was subjected to a catalytic Sharpless epoxidation 
with N,N-diisopropyltryptamine, L-(+)-DIPT, to afford 
the expected epoxy alcohol. Regioselective opening of 
the oxirane with allyl magnesium chloride,109 followed 
by Martinelli’s regioselective catalytic monotosylation to 
give 115110 in 81% overall yield, established the desired 
C12 stereocenter and set the stage for accessing lactol 117. 
To that end, the diol mono-tosylate 115 was first 
converted into the related bromohydrine 116 in 91% overall 
yield, by way of a base-assisted epoxide ring closing 
followed by LiBr-mediated ring opening.111 The sequence 
was completed by oxidative cleavage of the double bond, 
which took place with concomitant cyclization to the 
cis-bromolactol 117 in 91% yield over the last 2 steps. 
Cyclization of the lactol to afford 118 entailed a Friedel 
Crafts type alkylation, that was accomplished under Lewis 
acid promotion. Despite SnCl4 afforded high yields of this 
compound, the reaction required a large excess of the Lewis 
acid. This was overcome by employing catalytic amounts 
of Bi(OTf)3 in the presence of LiClO4 as a co-catalyst,112 
to furnish 118 in 94% yield within 3.5 h. 
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(HATU), Et3N, DMF (71%); 2. 2 mol L−1 KOH (aq.), dioxane-MeOH, 35 °C (60%).
Hydrogenolytic debenzylation of 118, followed by 
exposure of the resulting phenol 119 to TBAF under 
high temperature produced the intramolecular alkylative 
dearomatization of the latter,113 yielding 86% of the cage-
like dienone 120.
A sequential Hantzsch reagent-based (122) reduction 
of the dienone 120 in the presence of D-phenylalanine 
derivative 121, followed by a Pd/C-mediated catalytic 
hydrogenation afforded 73% of the expected cis-decalinic 
methoxyketone 123, admixed with the isomeric trans-
decalin (dr = 4:1). This was employed as a scaffold to 
functionalize both α-positions of the ketone. 
The installation of the conjugated double bond, which 
conducted to the synthesis of the key intermediate 125, was 
accomplished in three steps and 60% overall yield. This 
was initiated by demethylation of 123 with AlCl3/TBAI to 
yield 83% of 124,114 followed by mesylation of the resulting 
alcohol and thermally-assisted elimination of the mesylate 
with LiBr/Li2CO3 in DMSO.115 
On the other hand, the stereochemically correct 
attachment of the methyl and propionate side chains 
was carried out by successive α-alkylations with MeI 
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(80% yield of 126) and tert-butyl acrylate to give 62% of 
ester 127.116 TFA-mediated removal of the tert-butyl ester 
moiety gave quantitative amounts of platensic acid (128). 
This was followed by a HATU-assisted amidation (in 71% 
yield) of the just uncovered carboxylic acid moiety of 128 
with aniline derivative 129117 and final hydrolysis of the 
methyl ester to afford 60% of (−)-platensimycin (111). 
The synthesis took place in 21 steps for the longest linear 
sequence, with an overall yield of 3.8% from eugenol.
3. Synthesis of Analogs of Natural Products
3.1.  Synthesis of chrysantemic acid esters
Taking into account that eugenol itself is a repellent 
against mosquitoes and expecting to achieve functional 
synergy, a series of pyrethroids was synthesized by 
connecting various eugenol derivatives to chrysanthematic 
acid and other carboxylic acids. The insecticidal activity of 
the compounds was evaluated by an immersion method on 
the fourth instar larvae of Culex pipiens quinquefasciatus. 
The results revealed that the larvae were sensitive to the 
synthesized compounds.118 
3.2. Synthesis of an analog of rugulactone
Rugulactone (130), a naturally occurring pyrone, 
was isolated from the plant Cryptocaria rugulosa.119 
The compound is an efficient inhibitor of the nuclear 
factor (NK-κB) activation pathway. This factor has a 
major biological role, because once bonded to discrete 
DNA sequences, it can initiate gene expressions that are 
implicated in major diseases like cancer and diabetes. 
The rugulactone analog 131 was prepared (Scheme 15) 
during the synthesis of the natural product as a test of 
the key ring closing metathesis/cross-metathesis strategy 
towards the functionalized pyrone core.120 The synthesis 
entailed the Grubbs II-mediated reaction of triene 132 with 
eugenol, to afford 79% of intermediate 133, followed by 
DBU-assisted conjugative isomerization of the internal 
double bond of the latter, achieved in 52% yield.
3.3. Synthesis of a brominated analog of dihydrodieugenol
5,5’-Biphenyl structures occur frequently in softwood 
lignins because they arise from the symmetrical coupling 
of the corresponding monomers. Dehydrodieugenol (134) 
is the symmetrical dimer of eugenol (1).121 The compound 
(Scheme 16) is a conformationally flexible biphenyl 
derivative, which manifests biological activity comparable 
with that observed in eugenol, and others, such as 
antidepressant.122
The related O-methyldehydrodieugenol 134a123 and 
di-O-methyldehydrodieugenol 134c124 have been isolated 
from Ocotea cymbanum and Nectandra polita, respectively, 
whereas magnolol (134b), the symmetrical dimer of 
chavicol, was isolated from Magnolia officinalis.125 The 
presence of the allyl chains and the four oxygenated 
groups seem to be a chemostructural requirement for 
pharmacological activity.126
Dehydrodieugenol and 134b have been studied as 
antioxidant and anti-inflammatory agents.127 Compound 134 
is less toxic than eugenol and exhibits a stronger 
scavenging ability for superoxide radicals with respect to 
hydroxyl radicals (HO●) and a stronger inhibitory effect 
on lipid peroxidation.128 Therefore, it has inspired the 
synthesis of new biphenyls aiming to improved biological 
activities.129 
During the last 60 years, compound 134 has been 
synthesized repeatedly by chemical130 and biochemical131 
means, not always in satisfactory yield.132 On the other hand, 
compounds 134d and 134e have been recently prepared in 
combined 95% yield from dehydrodieugenol (134) by 
AlCl3-mediated demethylation.133 
Dehydrodieugenol (134) enhances the function 
of the gamma-aminobutyric acid (GABAA) receptor 
at concentrations higher than 3-10 mmol L−1.134 This 
compound, as well as its demethylated derivatives, were less 
potent as antiproliferative agents when evaluated against a 
panel of three cell lines (HL-60 PC-3 MOLT-4). Among the 
compounds 134 and 134a-c, only dehydrodieugenol (134) 
was inactive as antimicrobial against Staphylococcus 
aureus ATCC 29213, Methicillin resistant S. aureus 15187 
and Vancomycin resistant Enterococci.
Recently, atropoisomeric bromo-derivatives of 134 
have also been prepared. Eugenol was oxidized with 
K3Fe(CN)6 in an open flask, affording 95% of 134. This 
biphenyl was efficiently solved into the homochiral atropo-
O
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Scheme 15. Reagents and conditions: (a) 1 (3 equiv.), Grubbs II 
(2.5 mol%), CH2Cl2, reflux (70%); (b) 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) (0.1 equiv.), THF, RT, overnight (52%).
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diastereomeric bromo derivatives aR-137 and aS-137 by 
intermediacy of the di-(−)-menthyl dicarbonates 135. 
An exhaustive bromination of 135 to afford 136, 
followed by a selective zinc-mediated reductive dehydro-
debromination135 was devised in order to overcome the 
lack of selectivity for nuclear bromination, whereas a 
final reduction with LiAlH4 was required to remove the 
menthylcarbonate moieties. The dibromo-derivative proved 
to be C2-configurationally stable. The atropoisomers 137 was 
unable to modulate the function of the GABAA receptor. On 
the other hand, methylation of 134 with MeI/K2CO3 afforded 
natural product 134c in quantitative yield.
3.4. Synthesis of analogs of hallitulin
A concise synthesis of N-substituted 3,4-diarylpyrroles 
structurally related to the cytotoxic marine alkaloid halitulin 
(138) was reported (Scheme 17).136 The synthesis entailed 
the condensation of a phenacyl halide with a primary 
amine and a phenylacetaldehyde. Eugenol was employed 
as a starting material for the preparation of 139, one of the 
phenylacetaldehyde components. 
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Scheme 16. Reagents and conditions: (a) K3Fe(CN)6, O2, NH4OH, Me2CO-
H2O, RT (95%); (b) K2CO3, CH3I, DMF, 60 °C, 8 h (90%); (c) AlCl3, 
Me2S, RT, 1 h (134d:134e = 1:4, 95%); (d) (1R,2S,5R)-(−)-menthyl 
chloroformate, Et3N, PhMe, RT, 1 h (95%); (e) BTEA.Br3 (10 equiv.); 
(f) 1. ZnCl2, AcOH, 80 °C, 24 h (aS, 90%; aR, 95%); 2. LiAlH4, THF, 
0 °C → RT (aS137, 89%; aR137, 90%).
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Scheme 17. Reagents and conditions: (a) 1. 70% HNO3, AcOH (79%); 
2. OsO4, NaIO4, THF-H2O 0 °C → RT (82%); (b) 140, 141, NaI, MeOH 
(24%); (c) BBr3, CH2Cl2, RT (92%); (d) H2, Pd/C, EtOH (90%); (e) H2, 
Pd/C, EtOAc (77%).
The synthesis entailed the anchimerically-assisted 
ortho nitration of the phenol, followed by oxidative fission 
of the double bond to produce the acetaldehyde side chain. 
Compound 139 was condensed with bromoketone 140 
and diamine 141 to afford pyrrole derivative 142a. In 
turn this was transformed into compounds 142b-d by 
successive catalytic hydrogenations and BBr3-assisted 
demethylations.
One of the eugenol derivatives (142c) was found 
to be the analog with the highest cytotoxic activity, the 
mechanism of which involved in part an autophagic 
response, without any caspase-dependent cell death 
mechanism. This compound might be a useful lead for 
anticancer drug development.
4. Synthesis of Bioactive Compounds
Several bioactive compounds have been synthesized 
employing eugenol (1), as part of medicinal chemistry 
endeavors (Figures 2 and 3). The EP3 receptor is a 
member of the prostanoid G-protein coupled receptors. 
Prostanoids are products of the arachidonic acid cascade. 
Stark and co-workers137 synthesized structures with different 
small molecule fluorophoric moieties via a dimethylene 
spacer, which resulted in human EP3 receptor ligands 
such as 142, with affinities in the nanomolar concentration 
range. The compounds were visualized within the cells by 
confocal laser scanning microscopy and characterized as 
antagonists on human platelets.
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Quinoline moieties have been attached to the phenolic 
oxygen of eugenol, directly or through a spacer, in order 
to generate antiparasitary agents, potentially useful as 
antitrypanosomics against Trypanosoma cruzi (143)138 
or antileishmanial (144)139 agents. The attachment of 
a ligustrazine (tetramethylpyrazine) residue afforded 
compounds with protective effects against hydrogen 
peroxide (H2O2)-induced oxidative damage on ECV-304 
cells. Eugenol ether 146 proved to have a beneficial effect, 
protecting injured ECV-304 cells with an EC50 value of 
0.20 µM.140 
On the other hand, alkylation of the free phenol of 
eugenol and attachment of a trioxygenated aromatic 
ring to the end of the three-carbon side chain afforded 
cytotoxic compounds useful as breast cancer invasion 
inhibitors (145)141 and cancer chemopreventive agents 
(147).142 Other simple derivatives of eugenol have been 
prepared and examined as anticancer agents against 
different cell lines. Simple structure-activity relationships 
were obtained.143
Hydrothiolation of the double bond of eugenol with 
thiophenol derivatives afforded antioxidant compounds, 
such as 148, which were more effective in inhibition of 
induced lipid peroxidation compared to the precursor 
eugenol.144 Alkyl and aryl ethers of eugenol were effective 
in reducing lipid peroxidation, protein oxidative damage 
by carbonyl formation and increase total thiol content in 
cerebral cortex homogenates.145
1,3-Dipolar coupling of conveniently substituted 
eugenyl ethers with aldoximes resulted in pirazolines 
like 149, endowed with anti-stress activity.146 On the 
other hand, etherification of the free phenol of eugenol 
to produce mimetics of fibrates resulted in hipolipidemic 
compounds, such as 150,147 whereas introduction of the side 
chain of carvedilol afforded a new type of β-adrenoceptor 
blockers, with ancillary antioxidant activities; the receptor 
binding affinity of compound 151 was similar to that of 
propranolol.148
Alkylation of the free phenol moiety of eugenol 
with 3,5-diaryl pyrazoline amide derivatives resulted 
in antibacterial and antifungic agents. Compound 152 
exhibited significant antibacterial activity compared with 
gentamycin and moderate antifungal activity in comparison 
with griseofulvin.149 Simple derivatives of eugenol have 
also been evaluated for their antifungal activity.150 In 
addition, eugenol was employed as starting material for 
the synthesis of substituted dihydronaphthalenes,151 some 
of which exhibited activity as inhibitors of the efflux 
pump of Staphylococcus aureus. These agents have the 
ability to reduce the minimum inhibitory concentration 
of antibacterials, such as ciprofloxacin, when delivered 
associated with them. 
5. Cyclizations Involving Eugenol. Synthesis 
of Heterocycles
5.1. Synthesis of quinolines
The tetrahydroquinoline skeleton is an important 
heterocycle among natural products,152 and polysubstituted 
tetrahydroquinolines display a wide range of biologic 
activities, including antimalarial, antitumoral and 
antioxidant.153 
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Figure 2. Selected synthetic bioactive compounds prepared from eugenol.
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Figure 3. Selected synthetic bioactive compounds prepared from eugenol.
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Kouznetsov and co-workers154 designed a highly 
stereoselective synthesis of polysubstituted tetra-
hydroquinolines (156) from isoeugenol (3), obtained by 
solid base-mediated isomerization of eugenol (1), based 
on a three component imino Diels-Alder cycloaddition 
reaction (Scheme 18).155 The in situ preformed aldimines 
derived from benzaldehydes (154) and 3,4-(methylendioxy)
aniline 155 functioned as the azadiene component, whereas 
isoeugenol acted as the required dienophile. 
The t ransformation was best  performed in 
MeCN or polyethylenglycol (PEG) 400. A series of 
tetrahydroquinolines prepared after this methodology was 
tested as potential as cytotoxic and antitumor agents.156 
Interestingly, use of phthaldehydic acid as the aldehyde 
component enabled the formation of a isoindolo[2,1-a]
quinolin-11(5 h)-one, by lactamization157 of the acid 
moiety with the nitrogen atom of the tetrahydroquinoline. 
Compounds of this family were found to be active 
as protecting agents against N2-induced hypoxia and 
inhibitors of human topoisomerase II and bacterial DNA-
gyrase.158
On the other side, it is recognized that the quinolines are 
also an important class of heterocycles, and the quinoline 
skeleton is at the heart of numerous synthetic antimalarial, 
antibacterial, antifungal, anti-tuberculosis and anticancer 
compounds.159 Dinh and co-workers160 reported an efficient 
and simple new route towards substituted quinolines 
employing eugenol. Their sequence entailed protecting 
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Scheme 18. Reagents and conditions: (a) 10% KOH/Al2O3 (88%); (b) 10% 
BF3.Et2O, MeCN, 60 ºC, 6-10 h (40-64%); (c) ClCH2CO2Na; (d) HNO3, 
AcOH, –5 ºC, 4 h; RT, 4 h (80%); (e) 1. S2O4Na2, conc. NH3, RT, 6 h; 2. 
AcOH, 72 h (68%).
the free phenol with chloroacetic acid and subjecting the 
resulting compound (153) to nitration with fuming nitric 
acid in AcOH, which effected ether cleavage, a normal 
nitration, and then an unexpected electrophilic addition 
to the double bond to form 80% of the quinone-aci 
compound 157.161 In turn, derivative 157 was reductively 
cyclized in 68% yield, upon treatment with thiosulfate. It 
was conjectured that a Neff reaction of the primary nitro 
group afforded an intermediate aldehyde, which enabled the 
cyclization with the nitrogen atom attached to the cycle. The 
so obtained quinoline 158 could be further functionalized 
on C5 and on its free phenol moiety. 
5.2. Synthesis of isoquinolines
Since double bonds can be viewed as synthetic 
equivalents of alcohols, their hydrated counterparts, 
the capability of eugenol and eugenol derivatives to 
undergo cyclocondensations toward nitrogen and oxygen 
heterocycles was examined in several reaction sequences. 
One of them is a modification inspired in the Ritter-type162 
cyclocondensation of nitriles with dialkylbenzylcarbinols 
to access dihydroisoquinolines (Scheme 19), which was 
extended to allylbenzenes.163 
The free hydroxyl of eugenol was alkylated (MeI, 
EtI) almost quantitatively (2, 2a) under phase-transfer 
catalysis conditions (18-crown-6/KOH), and the Ritter 
cyclocondensation was performed with different nitriles, 
including HCN, MeCN, MeSCN, BnCN, ClCH2CN, 
homoveratryl nitrile and 3-cyanocoumarin, to yield 160. 
Under HBF4 as promoter, the reaction afforded 36% of 
the expected product (159),164 whereas the reaction of 2 with 
cyanoacetamide afforded the expected enaminoamides 161, 
even when eugenol itself was used as starting material. The 
use of 94% H2SO4 as cyclizing agent furnished lower yields 
of these latter compounds.165 
5.3. Synthesis of isochromanes
On the other hand, the most commonly used approach 
toward the pyran ring of isochromanes is the oxa-Pictet-
Spengler cyclization of β-phenylethyl alcohols with 
aldehydes and ketones.166 Since some isochromanes are 
relevant for their bioactivity as hypotensive, growth-
regulating and antitumor agents, modifications of this 
cyclization have been explored.167 The reaction of 
methyleugenol (2) with methyl trifluoropyruvate (163) 
under TfOH promotion directly afforded 84% of the 
isochromane derivative 163; the benzylic alcohol 162 was 
proposed as the intermediate, which undergoes cyclization 
with the allyl substituent. 
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5.4. Synthesis of coumarins
The reactivity of the free phenol moiety of eugenol 
was also employed to test the scope of a microwave-
assisted synthesis of coumarins (165) from phenols, 
with DMAD and PPh3.168 Mechanistically, initial 
addition of PPh3 to the acetylenic ester and concomitant 
protonation of the reactive 1:1 adduct, was proposed 
to be followed by electrophilic attack of the resulting 
vinyltriphenylphosphonium cation to the aromatic ring, at 
the ortho position relative to the phenolic strong activating 
group. The cyclized derivatives are then produced by 
lactonization. 
6. Synthesis of Macrocycles
6.1. Synthesis of crown ether derivatives
The Mannich reaction was employed for the synthesis 
in high yield of the bis-phenol aza-crown ether 167 
(Scheme 20), as potential membrane-forming amphiphile, 
from diaza-crown ether precursor 166.169 
Functional tests revealed that the stability of the 
amphisomes formed from these monomers is lower 
possibly because intramolecular hydrogen bonding 
prevents formation of intermolecular hydrogen bonds.
A series of macrocyclic tetralactones were prepared 
(Scheme 21), employing a ring closing metathesis operated 
by Grubbs’ I catalyst, as the key strategy toward the 
macroxyclization.170 
One of the examples included compound 172, 
which contains a couple of eugenol (1) moieties. This 
was prepared by ring opening-esterification of phthalic 
anhydride (168) with triethyleneglycol (169), followed 
by Steglich esterification (DCC-DMAP) of the resulting 
diacid (170) with eugenol, to produce 171 in 76% yield. 
Cyclization of the latter furnished the expected 35-member 
macrocycle 172 in 67% yield, as a 2:1 (E/Z) mixture of 
isomers. 
6.2. Synthesis of polysubstituted phthalocyanines
On the other hand, the phthalocyanines are an important 
group of organic functional materials. Their most important 
industrial application is the formation of color complexes 
with metal cations that are used as highly stable pigments 
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Scheme 19. Reagents and conditions: (a) KOH, 18-crown-6, PhH, 40-
60 °C, 2 h (ca. 100%); (b) AcOH, conc. H2SO4, 50-60 °C; 30 min or 94% 
H2SO4, 0 °C → RT, 15 min (52-82%); (c) AcOH, conc. H2SO4, 50-60 °C; 
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and dyes. Other uses include applications as photovoltaic 
materials in solar cells, systems for fabrication of light 
emitting diodes, liquid crystals and non-linear optical 
materials, sensitizers for photodynamic cancer therapy and 
dyes for recording layers for DVDs optical storage discs.
The unsubstituted phthalocyanine core is known for 
its insolubility in most common solvents. However, one of 
the main requirements for these compounds to be useful 
is that they should be soluble enough. In pursuit of that 
endeavor, Kantar and co-workers171 devised a three step 
synthesis of a series of phthalocyanines containing eight 
pendant eugenol moieties. 
Dichlorodicyanobenzene (173) was reacted with eugenol 
under base-catalyzed nucleophilic aromatic displacement 
conditions and the resulting bis-eugenyl ether (174) was 
tetramerized in refluxing quinoline (Scheme 22).172 In 
order to obtain the corresponding metallophthalocyanines, 
anhydrous transition metal salts [CuCl, NiCl2, CoCls, 
Zn(AcO)2 and Fe(CO)5] were employed under high 
temperature. The metallophthalocyanine products 175, 
obtained in 24-39% yield, were intensely green and very 
soluble in common organic solvents.
Kantar and co-workers171 also synthesized a series 
of phthalocyanines carrying more sophisticated side 
chains with four pendant eugenol units (Scheme 23). 
p-Hydroxyaniline (176) was diazotized and coupled 
with eugenol (1) and the phenolic moiety of the resulting 
product (178), obtained in 73% yield, was induced to 
displace the nitro group of 4-nitro-1,2-dicyanobenzene (180) 
under microwave irradiation, affording 76% of the 
monosubstituted phthalonitrile derivative intermediate 
179.173 The next transformations, involving tetramerization 
of 179, followed by introduction of the metallic cations 
toward 181 were performed under microwave irradiation.
7. Synthesis of Polymeric Materials
The design and development of new materials is 
one of the main areas of research in polymer science. In 
recent years, bio-based polymers (derived from renewable 
resources) have been attracting attention because of their 
potential advantages with regards to conservation of fossil 
resources and biodegradability. Renewable polymers are 
more structurally diverse; in addition, these materials can 
be considered carbon sinks, which are generated from CO2 
by a combination of plant photosynthesis and chemical 
manipulation. 
The increased use of sustainable polymers has the 
potential to reduce the amount of atmospheric CO2 in the 
short term, while being carbon neutral in the long term. 
The structural characteristics of eugenol and its commercial 
availability at low cost, transformed the natural product into 
a valuable building block for the design of new polymers.174 
Several researchers have attempted to use eugenol 
in synthetic polymer chemistry.  For example, 
Ciszewsky and Milczarek175 prepared polyeugenol by 
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electropolymerization, and examined its capacity to act as 
chemo- and biosensor. Bailly and co-workers176 synthesized 
bisphenol-A polycarbonate/eugenolsiloxane copolymers, 
whereas Peppas et al.177 studied the incorporation and 
release of eugenol from glassy hydrophilic copolymers. 
De la Mata and co-workers178 performed the 
hydrosilylation of the double bond of eugenol, preparing 
dendrimers with different properties, while Tappe et al.179 
examined Sharpless’ asymmetric dihydroxylation as 
a strategy towards polymer-bound olefins of different 
structural types. On the other hand, Masuda and co-
workers180 studied the Rh, Mo, and W catalyzed-
polymerization of eugenol derivatives carrying alkyne 
functionalities, and the synthesis of a bis(allyl)benzene 
diene derivative of eugenol, which was further submitted to 
acyclic diene metathesis polymerization,181 were disclosed. 
Eugenol can be engaged into oligomerization reactions. 
Triphenols 182 and 183 were prepared in 80% yields 
by tungstosilicic acid-assisted coupling of 2,6-bis-
hydroxymethyl phenols (184)182 with eugenol and related 
compounds, in aqueous medium (Scheme 24).183 These 
polyhydroxy aromatics play a versatile role in organic 
synthesis, especially for the preparation of calixarenes and 
macrocyclic crown ethers.
On the other hand, Shibata and co-workers184 oxidatively 
dimerized eugenol (1) to obtain 5,5’-bieugenol (134) and 
prepared the eugenol-formaldehyde polymer novolac (185). 
These authors pre-polymerized 1, 134 and 185 with 
4,4’-bismaleimide diphenylmethane (186) at 180 °C and 
then compression-molded the products at 250 °C for 6 h 
to produce cured 1/186 (EB), 134/186 (BB) and 185/186 
(NB) resins with eugenol/maleimide unit ratios of 1/1, 
1/2 and 1/3. Spectroscopic analysis suggested that EB 
resins arose from an ene reaction and subsequent Diels-
Alder/ene reactions, involving intermediates like 187-190 
(Scheme 25). However, BB resins and NB resins are the 
result of an ene reaction and subsequent thermal addition 
copolymerization. 
The glass transition temperature (Tg) and 5% weight 
loss temperature (T5) of the cured resin increased with 
increasing the content of 186, and EB resins 1/3 showed 
the highest Tg (377 °C) and T5 (475 °C). EB resins and 
NB resins exhibited higher flexural strengths and moduli 
than those of BB resins, with EB resin 1/2 showing the 
most balanced flexural strength and modulus (84.5 MPa 
and 2.75 GPa). 
Bifunctional monomers containing maleimide and 
allylphenyl groups were synthesized by the condensation 
of maleimidobenzoic acid chloride and eugenol. The ene-
addition reaction and Diels-Alder polymerization afforded 
new polyesters.185
Eugenol and rosin have been used as feedstocks for 
biobased epoxy resins. An epoxy component based on 
eugenol and an anhydride curing agent based on rosin were 
prepared and cured. The properties of the resulting material 
were studied, and the results suggest that the eugenol epoxy 
has similar reactivity, dynamic mechanical properties and 
thermal stability than commercial materials.186
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Functional assays demonstrated that the polymer 
exhibited bioactivity similar to that of eugenol and that 
the hydrolytic degradation of the polymer was complete in 
16 days, resulting in the release of eugenol and EDTA (194).
Anuradha and Sarojadevi191 prepared a series of 
bisphenols (198) containing a trimethylene spacer by 
treating eugenol (1) with 2,6-dimethyl phenol (195), 
o-cresol (196) and guaiacol (197) in the presence of AlCl3192 
and transformed these products into their respective bis-
cyanate esters 199 by treatment with CNBr (Scheme 27). 
Finally, the cyanate esters 199 were cyclotrimerized to 200 
by thermal curing.193 
Eugenol derivatives of higher chlorocyclophosphazenes 
and related epoxy oligomers were prepared and 
characterized. Oligomers with epoxy numbers of 15-16% 
and molecular masses from 1400 to 1800 were achieved.187 
Another important field of applied polymer science is 
the prevention of microbial contamination in the personal 
care and food industries for consumer protection. Taking 
into account that eugenol is known to possess antioxidant 
properties and antimicrobial activity against a range of 
bacteria, it was incorporated into poly(lactic-co-glycolic 
acid) (PLGA) nanoparticles. However, the nanoparticles 
exhibited a burst release of the active principle and nearly 
50% of the antimicrobial was released in the first 8 h.188 
Attempting to design a slower and more controllable 
release solution, Uhrich and co-workers189 synthesized, via 
solution polymerization, biodegradable poly(anhydride-
esters) composed of an ethylenediaminetetraacetic acid 
backbone and pendant eugenol groups as antimicrobials. 
Other phenolics, such as carvacrol and thymol were also 
prepared and tested.
The synthesis of the polymer involved ring-opening 
transesterification of the phenol (1) with EDTA dianhydride 
(191) in the presence of triethylamine to afford diacid 192 
in yields around 80% (Scheme 26), followed by solution 
polymerization to 193, with triphosgene as the coupling 
reagent, which prevented potential ring closure and 
regeneration of the EDTA dianhydride.190 
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The Tg values of the monomers were in the range of 
208-239 °C, whereas the Tg of the cured network depended 
on the length and symmetry of the monomer. The T10 
values of the resins were in the range of 364-381 °C, 
whereas physical parameters such as the limiting oxygen 
index (LOI) confirmed their thermal stability and flame 
retardancy capabilities.
Harvey et al.194 synthesized bisphenol 202 by the 
ruthenium-catalyzed cross-metathesis of eugenol, followed 
by hydrogenation of the resulting olefin 201. This common 
intermediate 202 was transformed into polycyanurate 204 
via the dicyanate 203, and into polycarbonate 205. The pure 
polycarbonate exhibited a Tg of 71 °C and polydispersity of 
1.88. An 80:20 blend of cyanate ester:polycarbonate was 
prepared and thermally cured, observing that the presence 
of the polycarbonate had no significant effect on the cure 
behavior of the cyanate ester. No phase separation was 
observed either during or after cure, suggesting that a 
homogenous network was generated. 
The resulting composite material exhibited a single Tg of 
132 °C, 55 °C lower than the Tg of the pure polycyanurate 
and 60 °C higher than the polycarbonate. Furthermore, 
the polycarbonate could be quantitatively separated from 
the thermoset matrix after cure by solvent extraction, 
proving the absence of chemical grafting under the curing 
conditions. These polymeric blends may have applications 
for fabrication of toughened composite structures. Other 
dicyanate monomers containing methylene spacers have 
also been prepared.195
Polybenzoxazines are a class of phenolic resins that 
possess dimensional and thermal stability and can be used 
as matrices for high performance composites with superior 
physical and mechanical properties.196 This is a relatively 
new family of phenolic resins which combine the thermal 
properties and flame retardance of phenolics, with the 
mechanical performance and design flexibility of epoxies. 
Polymerization takes place by thermal treatment, through 
the ring opening of the heterocyclic precursor monomers, 
without the need of catalysts and without producing by-
products or volatiles.197 
Benzoxazines are generated by the Mannich-like 
condensation of a phenol, formaldehyde and a suitable 
primary amine (Scheme 28);198 in the presence of secondary 
amines, benzylamine derivatives are usually formed.199 
Some eugenol-derived benzoxazines demonstrated to be 
lethal in the brine shrimp assay.200 
Muthusami and co-workers201 has recently prepared 
and polymerized several benzoxazines (207) from various 
aromatic diamines, like 206, and eugenol (1). They found 
that, unlike heterocycles resulting from other phenols, the 
allyl moiety of the eugenol-derived benzoxazines also 
participates during the curing process; this improves the 
cross-linking density of the polymer and leads to enhanced 
thermal stability (340 °C). 
Polymer nanocomposites are polymers that have been 
reinforced with small quantities of nanosized particles 
with large surface area and high aspect ratios (> 300). 
Their higher surface area to volume ratio convey to 
them enormous advantages over traditional micro or 
macroparticles.202 
Nanocomposites of eugenol-based polybenzoxazines/
amine-containing polyhedral oligomeric silsesquioxane 
(POSS, 208) have been prepared through co-polymerization 
of an eugenol-derived benzoxazine with an amino-
functionalized polyhedral oligomeric silsesquioxane 
(OAPS).203 POSS, which can be prepared in three steps 
and 73% yield from phenyl trichlorosilane (209),204 acts 
as good nanofiller and reduces the dielectric constant of 
the polybenzoxazines to 1.32, making them potentially 
suitable for use in microelectronics. In addition, the LOI 
values suggested that these products can be used for flame 
retardancy applications.
Silicone polycarbonates containing polydimethyl 
siloxane (213) and heptamethyl trisiloxane (211) moieties 
in the interior chain and terminal positions were recently 
synthesized (Scheme 29).205 The polymeric chains 
were capped with eugenol moieties. A bifunctional 
eugenosiloxane (214) was also used to include this 
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motif within the polymer (215). The silicon-derivatives 
of eugenol were prepared through a hydrosilylation 
reaction with 210 and 212, using Karstedt’s catalyst.206 
The polymers showed satisfactory thermo-oxidative 
stability and transparency. Their flexibility and wettability 
increased with increasing of the silicone content. Siloxane 
copolyesters containing phenylindane bisphenol, diphenyl 
terephthalate, and eugenol end-capped siloxanes, were 
prepared and characterized. The copolyesters were soluble 
in organic solvents and had film forming properties.207
Poly(phthalazinone ether nitrile) (PPEN) block 
copolymers (Scheme 30) with an hydrophobic surface 
(216) were prepared by the nucleophilic aromatic 
substitution polycondensation of eugenol end-capped 
polydimethylsiloxane (PDMS, 217) oligomers with fluoro-
terminated PPEN oligomers (218).208 
Polymers with eugenol moieties covalently bonded 
to the macromolecular chains were synthesized for 
potential application in orthopedic and dental cements 
(Scheme 31). The monomeric eugenol species were eugenyl 
methacrylate (219) and ethoxyeugenyl methacrylate (220), 
prepared in 80% yields by Fisher esterification. 
Polymerization of each of the novel monomers, at 
low conversion, provided soluble polymers 221 and 222, 
consisting of hydrocarbon macromolecules with pendant 
eugenol moieties. At high conversions, cross-linked 
polymers were obtained due to participation of the allyl 
side chain in the polymerization reaction. Co-polymers 
with ethyl methacrylate were also prepared. Analysis of the 
thermal properties, suggested that the eugenyl methacrylate 
derivatives are potentially good candidates for dental and 
orthopedic cements.209 
On the other hand, amino acid based synthetic polymers 
are expected to show biocompatibility and biodegradability 
similar to those of polypeptides.210 Optically active amino 
acid-based poly (N-propargylamide)s and poly(N-propargyl 
ester)s bearing eugenol moieties were synthesized in good 
yields, employing (2,5-norbornadiene)Rh+[η6-C6H5B−
(C6H5)3, a zwitterionic rhodium polymerization catalyst.211
The required eugenol-based monomers were prepared 
(Scheme 32) through the hydration of the double 
bond of methyl eugenol, achieved in 60% yield by 
reaction with formic acid, followed by hydrolysis of the 
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resulting formate 223 and conversion of the secondary 
alcohol 224 with triphosgene to afford 86% of the 
reactive chloroformate 225. Reaction of the latter with 
alanine furnished the alanyl intermediate 226, which was 
amidated (227) or esterified (228) in good yields.
The molecular weights of the polymers ranged from 
10800 to 17300. From their large specific rotation and 
circular dichroism signal, it was concluded that the 
polymers took a helical structure with a predominantly 
one-handed screw sense.212 A different behavior was 
observed between the poly(N-propargylamide)s and 
poly(propargyl ester)s. This was attributed to the presence 
and absence of hydrogen bonding between the side-chain 
amide groups, which seems to play an important role in 
the formation of helical conformations. 
8. Biotransformations and Biotechnology-
Related Uses and Applications of Eugenol
8.1.  Eugenol as feedstock. Production of fine chemicals
The TiO2-photocatalyzed production of vanillin from 
eugenol has been studied.213 However, biotechnological 
processes are usually less damaging to the environment 
than classical chemical processes and therefore considered 
as environmental friendly. Due to environmental concerns 
regarding the production processes for fine chemicals, 
recent research has shifted toward the exploitation of the 
metabolic and biocatalytic potential of microorganisms 
to transform readily available substrates into value-added 
products. The flavor and fragrances sector is a pioneer in 
this field.
Although eugenol is highly toxic for microorganisms 
even at low concentrations,214 there is a growing body of 
reports that point out to the natural product as one of the 
most suitable substrates for biotransformations because it 
is economic and readily available.215 The subject has been 
reviewed;216 however, the selected examples of Table 1 
and Scheme 33 evidenced that the biotechnology of the 
biotransformed products obtained from eugenol is still in 
its nascent stage.
Lambert and co-workers217 was able to use eugenol 
as a feedstock for the production of coniferyl alcoholm 
by introducing in S. cerevisiae the vaoA gene native to 
Penicillium simplicissimum, which encodes for the enzyme 
flavoenzyme vanillyl-alcohol oxidase. The resulting strain 
produced up to 16.9 g L−1 of alcohol products after a few 
days of culture, suggesting the ability to develop these 
essential oils as constituents of growth media, to signal 
for greater cellular activity of resistant strains of yeast, for 
their use in alcohol production.
8.2. Enzymatically-assisted synthesis of esters of eugenol
Esters of eugenol have been traditionally produced by 
chemical esterification of eugenol with acid chlorides.218 
Several compounds were chemically synthesized 
and evaluated as potential inhibitors of the enzyme 
lipoxygenase.219 In addition, eugenyl esters of aspirin, 
ibuprofen, 4-biphenylacetic acid (the active metabolite 
of fenbufen), mefenamic acid and indomethacin were 
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synthesized, in attempts to reduce the side-effects of 
the parent drugs,220 or produce synergy with the known 
properties of the natural product.221 
However, the enzymatic synthesis is an alternative to 
the chemical process.222 It offers some advantages including 
milder reaction conditions, low energy requirements, 
high product yields and purity, shorter reaction times, 
and biocatalyst reusability. Reactions are usually carried 
out in water-containing media; however, the solventless 
enzymatic synthesis of eugenol esters has also been 
reported.223
The enzymatic synthesis of eugenol benzoate by 
immobilized Staphylococcus aureus lipase was informed, 
as a strategy to modulate the antioxidant activity of the 
natural product.224 In the 1,1-diphenyl-2-picrylhydrazyl 
radical scavenging test, the IC50 values were found to 
be 18.2 versus 20.2 mg mL−1 for eugenol and eugenol 
benzoate, also evidencing antioxidant activities as high as 
90% of that of butylated hydroxytoluene (BHT), employed 
as comparator. 
Analogous preparations of eugenol caprylate and 
acetate have been reported. The former was synthesized 
using the commercial immobilized Thermomyces 
lanuginose lipase, Lipozyme TLIM, as the biocatalyst.225 
The biotransformation was statistically optimized, 
providing a maximum conversion yield of 72.2% under 
such conditions. On the other hand, eugenyl acetate was 
prepared employing Novozym 435, a commercial lipase 
from Candida antarctica immobilized on a macroporous 
Table 1. Production of small molecules of interest employing eugenol as substrate
Microorganism
Product Ref.
A B C D E F G H I J K
Amycolatopsis sp. HR167 (GM) × × × × × 226
Bacillus cereus PN24 × × × × × 227
Corynebacterium sp. × × × × × 228
Enterobacter sp. × 229
Escherichia coli (GM) × × × × 230
Pseudomonas fluorescens E118 × 231
Pseudomonas nitroreducens Jin1 × × × × 232
Pseudomonas resinovorans SPR1 × × × × × 233
Pseudomonas sp. × × × × × × 234
Pseudomonas sp. HR199 × × × × × 235
Pseudomonas sp. OPS1 × × × × × 236
Ralstonia eutropha H16 (GM) × × × 237
Saccharomices ceevisae 92411 (GM) × × 238
Streptomyces sp. × × × 239
A = ferulic acid; B = vanillin; C = vanillic acid; D = protocatechuic acid; E = keto-adipic acid; F = eugenol oxide; G = eugenol-diol; H = coniferyl alcohol; 
I = coniferyl aldehyde; J = guaiacol; K = 4-vinyl guaiacol. GM = genetically modified. 
anionic resin. The results indicated that the esterification 
of eugenol improved its antimicrobial properties.
8.3. Synthesis of eugenyl glycosides
Traditionally, glycosides have been synthesized by 
chemical means. For example, six eugenol glycosides, 
including 229 (Figure 4), were prepared by glycosylation 
of eugenol with various glycosyl bromides, followed by 
deacetylation with sodium methoxide in methanol, and their 
antifungal activity was assessed against Candida species. 
The peracetyl glycoside (230) was able to inhibit growth of 
C. albicans, C. tropicalis and C. glabrata, being 3.4 times 
more potent than fluconazole against C. glabrata, with low 
cytotoxicity (selectivity index of 45).226 
However, the paradigm is slowly changing toward the 
enzymatic synthesis of useful glycosides. Floral aroma is an 
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important factor in determining the quality of various fruits, 
flowers and teas.227 Various aroma constituents and other 
naturally occurring compounds are present in plants mainly 
as β-diglycoside precursors, such as β-primeverosides 
(6-O-β-D-xylopyranosyl-β-D-glucopyranoside); however, 
it is very difficult to obtain large amounts of the diglycosides 
from the natural sources. 
Therefore, Yamamoto and co-workers228 devised 
an enzymatic system, based on a partially purified 
β-diglycosidase from Penicillium multicolor IAM7153, for 
accessing several primaverosides. They prepared eugenyl 
β-primaveroside (231) in 12% yield by trans-glycosylation 
of p-nitrophenyl-β-primaveroside,229 along with other 
analogous primaverosides. The rate of formation of eugenyl 
β-primaveroside was too rapid and the compound was 
hydrolyzed 25-fold faster than analogous aliphatic aroma 
β-primaveroside.
De Winter et al.230 optimized a buffer/EtOAc biphasic 
system for the enzymatic transfer of glucose to a wide 
variety of acceptor molecules, taking advantage of the 
broad acceptor specificity of sucrose phosphorylase from 
Bifidobacterium adolescentis. Eugenol exhibited a rather 
moderate ability to undergo the transformation toward 232. 
However, eugenyl-α-D-glucopyranoside (232), prepared 
through catalysis by an amyloglucosidase from a Ryzopus, 
was found to be a potent inhibitor of the angiotensin 
converting enzyme (ACE, IC50 = 0.5 ± 0.04 mM),231 and to 
display other useful bioactivities, behaving like a prodrug 
of eugenol.232 The preparation of 232 by Xanthomonas 
maltophilia and with the aid of an α-glucosyl transfer 
enzyme of Xanthomonas campestris WU-9701 have also 
been reported.233
9. Concluding Remarks
Eugenol is a structurally simple, inexpensive and easily 
available small molecule natural product, which offers a 
wide range of application opportunities in bio/chemical 
synthesis. The various applications of eugenol, as feedstock 
for the chemo-enzymatic production of high valued 
low molecular weight compounds, as starting material 
for the synthesis of natural products and their analogs, 
and as building block for the elaboration of complexly 
functionalized bioactive compounds and co-drugs designed 
with improved physicochemical properties, macrocycles, 
heterocycles and polymers, fully justify considering 
eugenol as a highly versatile molecule. 
Taking into account the growing pressure toward 
replacing fossil-derived resources with more sustainable 
alternatives with regard to the easy availability, structural 
characteristics and unique reactivity of eugenol, it can 
be foreseen that Chemists will be increasingly seduced 
to choose the natural product as part of future synthetic 
endeavors. Therefore, it is expected that new, more complex 
and imaginative synthetic and biotechnologically-assisted 
solutions will be published in the near future, with eugenol 
or its simple derivatives at the center of the scene.
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